Neoadjuvant treatment for resectable pancreatic adenocarcinoma

doi:10.5306/wjco.v7.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8355)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

684

WORD

405

HTML

4332

Tables (1-2)

317

Sum=5738

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1090

Download

1527

Sum=2617

Feb 10, 2016 (publication date) through Feb 15, 2025

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Feb 10, 2016; 7(1): 1-8
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.1

Table 2 Selected ongoing neoadjuvant trials for resectable pancreatic cancer

Trial	Trial phase	Treatment regimen	Primary endpoint	Planned accrual (patients)
NCT01900327 (NEOPA)	III	Chemoradiation with gemcitabine and radiotherapy of 50.4 Gy vs upfront surgery	3 yr survival rate	410
NCT02172976	II/III	Perioperative FOLFIRINOX vs adjuvant gemcitabine	Median overall survival	126
NCT02047513 (NEONAX)	II	Perioperative nab-paclitaxel/gemcitabine vs adjuvant nab-paclitaxel/gemcitabine	Disease free survival	166
NCT02305186	I/II	Neoadjuvant pembrolizumab plus chemoradiation with capecitabine and radiotherapy of 50.4 Gy vs neoadjuvant chemoradiation	Dose limiting toxicities; # of tumor infiltrating lymphocytes per high power field in resected tissue	56

Citation: Wong J, Solomon NL, Hsueh CT. Neoadjuvant treatment for resectable pancreatic adenocarcinoma. World J Clin Oncol 2016; 7(1): 1-8
URL: https://www.wjgnet.com/2218-4333/full/v7/i1/1.htm
DOI: https://dx.doi.org/10.5306/wjco.v7.i1.1